KR20240146015A - 방사성 핵종 복합체의 대규모 합성 방법 - Google Patents

방사성 핵종 복합체의 대규모 합성 방법 Download PDF

Info

Publication number
KR20240146015A
KR20240146015A KR1020247028693A KR20247028693A KR20240146015A KR 20240146015 A KR20240146015 A KR 20240146015A KR 1020247028693 A KR1020247028693 A KR 1020247028693A KR 20247028693 A KR20247028693 A KR 20247028693A KR 20240146015 A KR20240146015 A KR 20240146015A
Authority
KR
South Korea
Prior art keywords
concentration
salt
mother liquor
iii
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247028693A
Other languages
English (en)
Korean (ko)
Inventor
도나토 바르바토
미셸 보
마티아 로세토
마티아 테데스코
페데리코 발레리오
Original Assignee
어드밴스드 엑셀러레이터 어플리케이션즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어드밴스드 엑셀러레이터 어플리케이션즈 filed Critical 어드밴스드 엑셀러레이터 어플리케이션즈
Publication of KR20240146015A publication Critical patent/KR20240146015A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247028693A 2022-02-04 2023-02-03 방사성 핵종 복합체의 대규모 합성 방법 Pending KR20240146015A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263306822P 2022-02-04 2022-02-04
US63/306,822 2022-02-04
PCT/IB2023/050982 WO2023148680A1 (en) 2022-02-04 2023-02-03 Methods for large scale synthesis of radionuclide complexes

Publications (1)

Publication Number Publication Date
KR20240146015A true KR20240146015A (ko) 2024-10-07

Family

ID=85221934

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247028693A Pending KR20240146015A (ko) 2022-02-04 2023-02-03 방사성 핵종 복합체의 대규모 합성 방법

Country Status (9)

Country Link
US (1) US20260053959A1 (enExample)
EP (1) EP4472678A1 (enExample)
JP (1) JP2025506322A (enExample)
KR (1) KR20240146015A (enExample)
CN (1) CN118159303A (enExample)
CA (1) CA3235923A1 (enExample)
IL (1) IL313964A (enExample)
TW (1) TW202342112A (enExample)
WO (1) WO2023148680A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025029946A1 (en) * 2023-07-31 2025-02-06 Curium Us Llc [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
WO2025210599A2 (en) 2024-04-05 2025-10-09 Novartis Ag Combination therapies with dna damage response inhibitors and [ 177lu]lu-psma-617

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020021310A1 (en) * 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) Srl Stable, concentrated radionuclide complex solutions
LT4541381T (lt) * 2018-07-25 2026-03-25 Advanced Accelerator Applications S.A. Stabilūs, koncentruoti radionuklidų kompleksų tirpalai
EP3666451B1 (en) 2018-10-18 2021-03-03 Mitsubishi Electric Corporation Additive manufacturing machine and cooling method
CA3159337A1 (en) * 2018-10-31 2020-05-07 Advanced Accelerator Applications (Italy) Srl Methods for synthesis of radionuclide complex
SG11202113333SA (en) * 2019-06-14 2021-12-30 Edinburgh Molecular Imaging Ltd Compounds and methods of use

Also Published As

Publication number Publication date
JP2025506322A (ja) 2025-03-11
CA3235923A1 (en) 2023-08-10
EP4472678A1 (en) 2024-12-11
US20260053959A1 (en) 2026-02-26
IL313964A (en) 2024-08-01
WO2023148680A1 (en) 2023-08-10
TW202342112A (zh) 2023-11-01
CN118159303A (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
KR102767449B1 (ko) 방사성핵종 착물의 합성 방법
AU2007284570B2 (en) Automated system for formulating radiopharmaceuticals
WO2020021310A1 (en) Stable, concentrated radionuclide complex solutions
EP3965751B1 (en) Para-aminohippuric acid (pah) as a renal protective substance
KR20240146015A (ko) 방사성 핵종 복합체의 대규모 합성 방법
US20090155167A1 (en) Automated method
US20210379212A1 (en) Stable, concentrated radionuclide complex solutions
CN116806144A (zh) 放射性核素络合物的稳定制剂
JP2025506001A5 (enExample)
EP3452436B1 (en) In-kit preparation of gallium-68 labelled radiopharmaceuticals
KR101855509B1 (ko) 방사성 의약품의 제조를 위한 바이알 키트 및 이를 이용한 방사성 의약품의 제조 방법
RU2826739C2 (ru) Способы синтеза радионуклидного комплекса
RU2859685C2 (ru) Фармацевтическая композиция в форме раствора для внутривенного введения на основе металлокомплексов бета-эмиттеров: лютеций-177 или тербий-161 и агонистов соматостатиновых рецепторов: DOTA-TATE, DOTA-TOC, DOTA-NOC
WO2023164769A1 (en) Radiopharmaceutical and methods

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000